Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company at the forefront of developing next-generation cellular immunotherapies for cancer and immune disorders. Utilizing its proprietary induced pluripotent stem cell (iPSC) product platform, the company engineers 'off-the-shelf' natural killer (NK) and T-cell product candidates. These therapies are designed to be universally available, overcoming limitations of patient-specific treatments. Fate Therapeutics aims to deliver transformative treatments by harnessing the power of the immune system through precisely engineered, renewable cell sources.
The San Diego headquarters serves as the central hub for Fate Therapeutics' research and development, clinical operations, cGMP manufacturing, and corporate administration.
The facility includes state-of-the-art laboratories for iPSC research, cell engineering, cGMP manufacturing, and process development, alongside modern office spaces designed to foster collaboration.
As a cutting-edge biotech firm, the work culture at Fate Therapeutics' HQ is characterized by innovation, scientific rigor, collaboration among multidisciplinary teams, and a strong sense of purpose driven by the potential to impact patient lives.
Located in a prominent San Diego biotech cluster, the headquarters benefits from proximity to leading research institutions, a rich talent pool, and a vibrant ecosystem of life science companies, fostering innovation and partnership opportunities.
While Fate Therapeutics is headquartered in the United States, its impact and operations are global. The company conducts clinical trials for its iPSC-derived cell therapies in multiple countries, collaborating with international research institutions and clinical sites. The 'off-the-shelf' nature of its product candidates aims for worldwide accessibility, positioning Fate to address patient needs across diverse geographical regions. Their research and development efforts also contribute to the global scientific understanding of cellular immunotherapies.
12278 Scripps Summit Drive
San Diego
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Fate Therapeutics, Inc.' leadership includes:
Fate Therapeutics, Inc. has been backed by several prominent investors over the years, including:
Fate Therapeutics has made significant strategic appointments to its executive team over the past year (May 2023 - May 2024), notably strengthening its scientific, medical, and technical leadership with new C-suite executives. This includes new Chief Scientific, Chief Medical, and Chief Technical Officers, and a key transition for the former CSO to an advisory role.
Discover the tools Fate Therapeutics, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Fate Therapeutics, Inc. likely utilizes common corporate email formats. Based on standard practices, a common structure involves the first initial followed by the last name, or the first name separated from the last name by a dot, preceding the '@fatetherapeutics.com' domain.
[first_initial][last]@fatetherapeutics.com
Format
swolchko@fatetherapeutics.com
Example
75%
Success rate
Fate Therapeutics / Business Wire • May 9, 2024
Fate Therapeutics announced its financial results for Q1 2024, highlighting progress in its iPSC-derived NK and T-cell therapy programs. Key updates included advancements in clinical trials for FT522 in B-cell lymphoma and FT819 in B-cell malignancies, along with a strong cash position to fund operations....more
Fate Therapeutics / Business Wire • April 8, 2024
Fate Therapeutics announced presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, showcasing preclinical data for FT522 (IFN-alpha armored CAR NK cell) and FT825/ONO-8250 (multiplexed-engineered CAR T-cell), highlighting their potential in cancer treatment....more
Fate Therapeutics / Business Wire • February 27, 2024
Fate Therapeutics reported its Q4 and full-year 2023 financial results, providing updates on its clinical programs, including the FT522 and FT819 studies, and its ongoing collaboration with ONO Pharmaceutical for FT825/ONO-8250. The company emphasized its focused strategy on advancing its core programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Fate Therapeutics, Inc., are just a search away.